A
B
C
D
F
G
H
I
K
L
M
N
O
P
Q
R
S
T
V
W
Y
A Top B Top
C Top
D Top
F Top
G Top
H Top
I Top
K Top
L Top
M Top
N Top
O Top
P Top
Q Top
R Top
S Top
T Top
V Top
W Top
Y Top
A Top B Top
Bzlglyggftgarksark-nh2 | |
Bzlglyggftgarksarklknq-nh2 |
C(rgdfmef) | |
C(rgdfmev) | EMD-12192; EMD-121974; CILENGITIDE; cyclo(Arg-Gly-Asp-D-Phe-[N-Me]Val) |
Cyclo(cyiqncplg) | |
Cyclo(cyiqncplgagagag | |
Cyclo(rgdfv) (control) | |
Cyclo[ghqmfyybta]-nh2 | |
Cyclo[gldnkmifwybta]-nh2 | |
Cyclo[rgdfk(cypate)] |
Dcrsdtlcge-nh2 | |
Dipeptide ligand | |
Dota-reccehdfrwckpv-nh2 | |
Dota-reccehdfrwckpv-oh | |
Dota-reccehdfrwckpvd-oh | |
Dota-reccehdfrwcrpv-nh2 | |
Dprwfwll-nh2 | |
Dwfwll-nh2 |
Fllrdpqdk-nh2 | |
Fv-aib-tdvgpfaf | |
Fv-hop-tdvgpfaf | |
Fv-hyp-tdvgpfaf | |
Fv-tic-tdvgpfaf | |
Fvptdvg-acp-faf | |
Fvptdvg-aib-faf | |
Fvptdvg-hyp-faf | |
Fvptdvg-pac-faf |
Iacnckrhvikphicrkicgkn-nh2 | |
Icvvqdwghhrct-nh2 | COMPSTATIN |
Iii-btd | NOCICEPTIN RECEPTOR ANTAGONIST PEPTIDE III-BTD |
Ikcnckrhviaphicrkicgkn-nh2 | |
Ikcnckrhvikahicrkicgkn-nh2 | |
Ikcnckrhvikphicraicgkn-nh2 | |
Ikcnckrhvikphicrkicgan-nh2 | |
Ikcnckrhvikphicrkicgkn-nh2 | |
Ilpwgwpwwpwpp-nh2 | |
Ilpwgwpwwpwrr-nh2 | |
Ilpwkwpwwpwp-nh2 | |
Ilpwkwpwwpwpp-nh2 | |
Ilpwkwpwwpwrr-nh2 |
Ksg-ldtknykqtsv | |
Kwfwll-nh2 |
L-brpmp-oh | |
Lpnynwnsfglrf-nh2 | |
Lpnynwnsflrf-nh2 | |
Lpwkwpwwpwpp-nh2 | |
Lrhylnlltrqry-nh2 |
Macrocyclic tripeptide motif |
N3-ghqmfyypra-nh2 | |
N3-gldnkmifwypra-nh2 | |
Ndp-sysmehfrwgkpvg | |
Neuropeptide y(npy) | Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr; Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-OH |
Neuropeptide-y | neuropeptide Y; human Neuropeptide Y; Nucleopeptide Y(NPY)(YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY) |
Ngyeiewyswvthgmy-nh2 |
Octadecapeptide venom | Apamin |
Pentapeptide inhibitor 2 | |
Peptide boronate | |
Phe-ggftgarksarklad-glu | FGGFTGARKSARKLADE |
Pkyvkqntlklat | |
Pmp lpqtv | gp130 (904) derived peptide, 28 |
Pvkrrlf-nh2 |
Qetayfllklagr-conh2 | |
Qwfwll-nh2 |
Rpkpfqwfwll-nh2 | |
Rwfwll-nh2 |
Sfllr-nh2 | P5-NH2; CAS_141923-41-3 |
Sfllrdpqd-nh2 | |
Sfllrdpqdk-nh2 | |
Sfllrdpqdk-oh | |
Sfllrdpqdkyepf-oh | |
Sfllrn-nh2 | CAS_141923-40-2 |
Sttvkaaswwa-conh2 |
Tasfllklagrw-nh2 | |
Tayfllklagrl-nh2 | |
Tetrapeptide inhibitor 1 | |
Tpa lpqtv | gp130 (904) derived peptide, 27 |
Vasoactive intestinal polypeptide | CAS_37221-79-7 |
Vthrlagllsrsggvvknnfvptnvgskaf-nh2 |
Wfwgg-nh2 | |
Wfwll-nh2 | |
Wtlnsagyll-conh2 | |
Wtlnsagyllgphavgnhpsfsdknglts-conh2 | |
Wvthrlagllsrsggvvknnfvptnvgskaf-nh2 |
Y lpqtv | gp130 (904) derived peptide, 25 |
Y(p)apqtv | gp130 (904) derived peptide, 20 |
Y(p)fkqnc | gp130 (813) derived peptide, 5 |
Y(p)hnqpl | EGFR (1086) derived peptide, 12 |
Y(p)inqsv | EGFR (1068) derived peptide, 11 |
Y(p)kpqmh | LIFR (1001) derived peptide, 9 |
Y(p)laqtv | gp130 (904) derived peptide, 21 |
Y(p)lkqes | |
Y(p)lpatv | gp130 (904) derived peptide, 22 |
Y(p)lpetv | gp130 (904) derived peptide, 29 |
Y(p)lpntv | gp130 (904) derived peptide, 30 |
Y(p)lpqav | gp130 (904) derived peptide, 23 |
Y(p)lpqta | gp130 (904) derived peptide, 24 |
Y(p)lrcds | GCSFR (748) derived peptide, 16 |
Y(p)qkqtr | |
Y(p)qpqak | LIFR (981) derived peptide, 8 |
Y(p)rhqvp | gp130 (767) derived peptide, 4 |
Y(p)rpqam | LIFR (1028) derived peptide, 10 |
Y(p)sdgnf | gp130 (673) derived peptide, 2 |
Y(p)stvvh | gp130 (759) derived peptide, 3 |
Y(p)vlqgd | GCSFR (708) derived peptide, 15 |
Yaga-vvndl | NH2-YAGAVVNDL-COOH; Tyr-Ala-Gly-Ala-Val-Val-Asn-Asp-Leu; Tyr-D-Ala-Gly-Ala-Val-Val-Asn-Asp-Leu; H-Tyr-Ala-Gly-Ala-Val-Val-Asn-Asp-Leu-OH |
Yfllkl-nh2 | |
Ygrkkrrqrrr-klssiesdv |